U.S. Markets

Sarepta Therapeutics (SRPT) reaffirms FY26 sales forecast between USD 1.2-1.4bln; management guides towards lower end of range

1 stocks

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more